2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
June 30th, 2025
Version: 1
Istituto di Tecnologie Biomediche (ITB-CNR
cancer biology
biorxiv

Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of Resistance

Maroni, G.Open in Google Scholar•Cabrera San Millan, E.Open in Google Scholar•Mercatelli, R.Open in Google Scholar•Chiodi, A.Open in Google Scholar•Campanella, B.Open in Google Scholar•Onor, M.Open in Google Scholar•Modeo, L.Open in Google Scholar•Braccini, G.Open in Google Scholar•Cercignani, G.Open in Google Scholar•Ali, A.Open in Google Scholaret al.

Osimertinib (Osi) resistance remains a significant challenge in EGFR mutant non-small-cell lung cancer (NSCLC). This study investigates the metabolic reprogramming associated with Osi resistance, identifying key metabolic vulnerabilities that may be targeted for therapeutic intervention. Employing the EGFR-mutant H1975 parental (Par) cell line and its Osi-resistant (OsiR) counterpart, we integrated transcriptomics, metabolomics, nuclear and mitochondrial genomics, functional assays and bioanalytical techniques, as well as advanced 3D imaging to comprehensively define the resistant phenotype. We found that OsiR cells exhibit mitochondrial dysfunction, including impaired oxidative phosphorylation (OXPHOS), mitochondrial DNA mutations, and altered mitochondrial gene expression. To describe this systems-level characterization, we introduce the concept of mitochondromics, a comprehensive profiling of mitochondrial genomic, transcriptomic, structural, and functional changes contributing to therapeutic resistance. Metabolomic profiling revealed a significant accumulation of glycolytic intermediates (lactate, pyruvate, acetate, and acetaldehyde) in the extracellular medium, indicating a shift toward glycolysis and activation of alternative metabolic pathways, including the Warburg effect. Notably, we identified the pyruvate-acetaldehyde-acetate (PAA) pathway as a functionally repurposed metabolic route that facilitates NADPH production, which is critical for antioxidant defense and anabolic processes in OsiR cells. Additionally, although the pentose phosphate pathway (PPP) is not the primary source of NADPH in OsiR cells, it plays a supporting role in biosynthesis, contributing to the production of amino acids, nucleotides, and vitamins. Altered expression of enzymes involved in glycolysis, the TCA cycle, and both oxidative and non-oxidative arms of the PPP further supports an adaptive metabolic network promoting cell growth and resistance to Osi. This study reveals a complex metabolic reprogramming in Osi-resistant EGFR-mutant NSCLC, where a newly identified role for the PAA pathway, alongside integrated mitochondromic alterations emerges as key driver of resistance. These insights uncover potential metabolic vulnerabilities of Osi-resistant tumors and provide a foundation for developing therapeutic strategies to counteract resistance and improve osimertinib efficacy. Targeting these metabolic pathways may offer promising avenues for overcoming resistance in clinical settings.

Similar Papers

biorxiv
Mon Jun 30 2025
Decoding Breast Cancer Heterogeneity via Multi-Omics Integration and Language Model-Based Interpretation
We present a novel pipeline combining Multi-Omics Factor Analysis (MOFA) and fine-tuned Large Language Models (LLMs) to predict breast cancer subtypes using proteomics, DNA methylation, and RNA-Seq data. Breast cancer is a heterogeneous disease characterized by diverse molecular alterations across multiple biological layers, necessitating integrative approaches for accurate subtype classification....
Yasrab, R.
•
Agrawal, R.
•
Saber-Ayad, M.
•
El-Hadidi, M.
biorxiv
Mon Jun 30 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Accurately predicting which patients will respond to immune checkpoint blockade (ICB) remains a major challenge. Here, we present TIME_ACT, an unsupervised 66-gene transcriptomic signature of tumor immune activation derived from TCGA melanoma data. First, TIME_ACT scores accurately identify tumors with activated immune microenvironments across cancer types. Analysis of spatial features of the tumo...
Mukherjee, S.
•
Patiyal, S.
•
Pal, L. R.
•
Chang, T.
...•
Ruppin, E.
biorxiv
Mon Jun 30 2025
Vinorelbine enhances the efficacy of GM-CSF-armed oncolytic vaccinia virus in a preclinical model of ovarian high grade serous carcinoma
Vaccinia virus, known for its clinical safety has a tropism for primary and metastatic tumours as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer. Unfortunately, oncolytic vaccinia monotherapies are yet to live up to their potential promise. Given this, there is a need to identify combination agen...
Drymiotou, S.
•
Queval, C. J.
•
Tyson, K. E.
•
Sheach, L. A.
...•
Way, M.
biorxiv
Mon Jun 30 2025
Intratumoral Treg ablation is sufficient to mediate tumor control systemically without autoimmunity
Regulatory T cells (Tregs) infiltrate most tumors, yet whether they suppress immune responses directly within tumor tissues is untested. We used intratumoral (IT) delivery of diphtheria toxin (DT) in Foxp3DTR mice to deplete IT Tregs while leaving peripheral Tregs intact. IT delivery of DT reduced Treg frequencies in the tumor, which promoted potent tumor control without autoimmunity. Interestingl...
Bockman, A.
•
Gittins, B.
•
Zhang, C.
•
Hung, J.
...•
DuPage, M.
biorxiv
Mon Jun 30 2025
CD47 blockade enhances immunoradiotherapy response in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is a significant cause of morbidity and mortality worldwide, with limited treatment options for patients with locally advanced disease. CD47 immune checkpoint inhibitors have been used to block the CD47/SIRPa interaction that inhibits antigen-presenting cell phagocytosis, thereby enhancing antigen presentation to cytotoxic T-cells, and have shown promi...
Monther, A.
•
Al-Msari, R.
•
Saddawi-Konefka, R.
•
Fassardi, S.
...•
Califano, J.
biorxiv
Mon Jun 30 2025
NK cell co-localization with epithelial cells in pancreatic cancer is influenced by fibroblasts and ECM components
Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive and common type of pancreatic cancer. PDAC has a dense, fibrotic tumor microenvironment (TME) that restricts immune cell infiltration and contributes to poor immunotherapy responses. While T cell-based therapies have been largely ineffective, natural killer (NK) cells-which kill tumor cells without requiring MHC recognition-offer a pro...
Malchiodi, Z. X.
•
Lekan, A. A.
•
Suter, R. K.
•
Deshpande, A.
...•
Weiner, L. M.
biorxiv
Mon Jun 30 2025
Targeting breast cancer senescence in 3D models of bone metastasis
Chemotherapeutic treatment of breast cancer with Doxorubicin can induce tumor and stromal cell senescence leading to therapy-resistance. Senescence-associated secretory phenotype (SASP) promotes secretion of pro-inflammatory and tumorigenic factors causing systemic inflammation. Combined, this can result in immune suppression, tumor growth and secondary spread of cancer. Targeting and removing sen...
Hamburger, E. C. B.
•
Mohseni Garakani, M.
•
Alfaisali, S.
•
Ouellet, J. A.
...•
Rosenzweig, D. H.
biorxiv
Mon Jun 30 2025
Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathology
Accurately predicting which patients will respond to immune checkpoint blockade (ICB) remains a major challenge. Here, we present TIME_ACT, an unsupervised 66-gene transcriptomic signature of tumor immune activation derived from TCGA melanoma data. First, TIME_ACT scores accurately identify tumors with activated immune microenvironments across cancer types. Analysis of spatial features of the tumo...
Mukherjee, S.
•
Patiyal, S.
•
Pal, L. R.
•
Chang, T.
...•
Ruppin, E.
biorxiv
Sun Jun 29 2025
Riboflavin drives nucleotide biosynthesis and iron-sulfur metabolism to promote acute myeloid leukemia
Riboflavin is a diet-derived vitamin in higher organisms that serves as a precursor for flavin mononucleotide and flavin adenine dinucleotide, key cofactors that participate in oxidoreductase reactions. Here, using proteomic, metabolomic and functional genomics approaches, we describe a specific riboflavin dependency in acute myeloid leukemia and demonstrate that, in addition to energy production ...
Bjelosevic, S.
•
Fauth, R.
•
Do, B. T.
•
Alexe, G.
...•
Stegmaier, K.